We thank the Wellcome Trust Integrative Physiology Initiative in Ion Channels and Diseases of Electrically Excitable Cells (OXION) for use of the microarray facility.
We thank C. Lister and P. Kirk for their assistance and W. Lian for his assistance in designing the eIF4E siRNA, J. Hiscott, E. Hernandez and P. Wilkinson for the use of the microarray facilities and statistical analyses, O. Meyuhas, P. Bitterman, B. Shapiro, N. Colburn, M. Miron and A.-C. Gingras for critical comments on the manuscript.
The CATMA V2.3 microarray [ 149] of the Microarray Facility of the University Hospital Leuven (MAF, Leuven, Belgium, ArrayExpress accession no. A-MEXP-120) was used for this study.
First, 70-mer oligonucleotide arrays, which are routinely used in the Utrecht microarray facility, were used as proof of principle.
The use of microarrays, though attractive, is out of reach for many researchers without access to costly facilities, supplies, and technicians required to process tissue for gene expression and interpret results.
Maintenance of the microarray facility was supported by the High-Tech Research Center at Kanazawa Medical University.
Also thanks to Prof Andrew Cossins (University of Liverpool) for the use of their microarray printing facilities and Dr Margaret Hughes for printing.
After RNA extraction from fibroblast clones in the exponential growth phase of similar passages (P12 18), microarray gene expression analyses were performed using Affymetrix GeneChip HT HG-U219 platesatray plathe at the Microarray Facility Tuebingen (MTF Services, Medical Genetics, Tuebingen, Germany).
CGH BAC microarrays produced at the Microarray facility of the VU Medical Center were used.
Quality control, conversion to labeled RNA, hybridization and scanning were all performed at the microarray facility of the Department of Human Genetics Radboud University Nijmegen Medical Centre NijmegenNijmegengen, the Netherlands), using Affymetrix technology while following the manufacturer's protocols.
